Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma - PubMed (original) (raw)
Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma
Marco Cosentino et al. World J Urol. 2013 Feb.
Abstract
Objective: To investigate the existence of predictive factors for concomitant, primary UUT-UCC and BC. Upper urinary tract urothelial cell carcinoma (UUT-UCC) is a pan-urothelial disease of the transitional epithelial cells. Although several studies have shown the association of bladder recurrence following UUT-UCC, little is known on the incidence of concomitant UUT-UCC and bladder cancer (BC) without previous BC.
Materials and methods: A retrospective review of 673 patients diagnosed and treated for UUT-UCC was performed. Patients with history of BC were excluded. We investigated age, sex, location of the upper tract tumor (calyx, renal pelvis, upper ureter, mid-ureter, lower ureter), multifocality, clinical symptoms, tumor grade and pathological stage. Contingency tables and chi-square test were used for categorical variables and analysis of variance (ANOVA) for quantitative variables.
Results: 450 patients eligible for inclusion were identified. Of these, 76 (17 %) presented concomitant primary UUT-UCC and BC. Location of primary UUT-UCC was in calyx and/or renal pelvis in 25 patients (34 %), upper ureter 8 (11 %) and lower ureter 37 (49 %). In 6 patients (8 %), data were missing. Concomitant BC was found in 10, 18, and 33 % of patients with primary caliceal/renal pelvis, upper ureter and lower ureter UUT-UCC, respectively. On multivariate analysis, location of UUT-UCC was the only predictive factor for concomitant bladder tumor (OR: 1.7; 95 % CI, 1.007-2.906 p = 0.047).
Conclusions: Our findings suggest that the possibility of concomitant BC in primary diagnosed patient with UUT-UCC is as high as 33 % and mainly depends on upper tract tumor location.
Similar articles
- [Primary upper urinary tract tumors and subsequent location in the bladder].
Azémar MD, Audouin M, Revaux A, Misraï V, Comperat E, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Rouprêt M. Azémar MD, et al. Prog Urol. 2009 Oct;19(9):583-8. doi: 10.1016/j.purol.2009.03.007. Epub 2009 May 9. Prog Urol. 2009. PMID: 19800544 Review. French. - [European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].
Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W; European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract. Rouprêt M, et al. Actas Urol Esp. 2012 Jan;36(1):2-14. doi: 10.1016/j.acuro.2011.09.001. Epub 2011 Oct 29. Actas Urol Esp. 2012. PMID: 22036956 Spanish. - Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival.
Milojevic B, Djokic M, Sipetic-Grujicic S, Milenkovic-Petronic D, Vuksanovic A, Dragicevic D, Bumbasirevic U, Tulic C. Milojevic B, et al. Int Urol Nephrol. 2011 Sep;43(3):729-35. doi: 10.1007/s11255-011-9902-4. Epub 2011 Feb 26. Int Urol Nephrol. 2011. PMID: 21350863 - The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract.
Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, Chiang PH, Shiue YL. Kang CH, et al. Cancer. 2003 Oct 15;98(8):1620-6. doi: 10.1002/cncr.11691. Cancer. 2003. PMID: 14534877 - The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC).
Audenet F, Yates DR, Cussenot O, Rouprêt M. Audenet F, et al. Urol Oncol. 2013 May;31(4):407-13. doi: 10.1016/j.urolonc.2010.07.016. Epub 2010 Sep 29. Urol Oncol. 2013. PMID: 20884249 Review.
Cited by
- A new surgical technique of robotic-assisted laparoscopic nephroureterectomy without re-docking in a single position: a single center experience.
Xu D, Liu H, Lei Y, Wang W, Cui X, Shen H. Xu D, et al. J Robot Surg. 2024 Oct 7;18(1):362. doi: 10.1007/s11701-024-02111-5. J Robot Surg. 2024. PMID: 39370475 - Intravesical hexyl-aminolevulinate used to detect upper tract carcinoma in situ during surveillance ureteroscopy: A case report and review.
Klose C, Gibbs EM, Waddell B, Baird B, Lyon T, Pak R. Klose C, et al. Urol Case Rep. 2024 Aug 28;56:102841. doi: 10.1016/j.eucr.2024.102841. eCollection 2024 Sep. Urol Case Rep. 2024. PMID: 39280128 Free PMC article. - Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract.
Chan KH, Shu T, Al Shaarani M, Cen P. Chan KH, et al. J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241257333. doi: 10.1177/23247096241257333. J Investig Med High Impact Case Rep. 2024. PMID: 38804541 Free PMC article. - Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
Kdimati S, Christoph C, Glass Ä, Engel N, Dräger DL, Maletzki C, Becker AS, Zimpfer A. Kdimati S, et al. Int J Mol Sci. 2024 Mar 20;25(6):3492. doi: 10.3390/ijms25063492. Int J Mol Sci. 2024. PMID: 38542462 Free PMC article. - Diagnostic Value of Urine Cytology in Pharmacologically Forced Diuresis for Upper Tract Urothelial Carcinoma Diagnosis and Follow-Up.
Giudici N, Blarer J, Sathianathen N, Burkhard FC, Wuethrich PY, Thalmann GN, Seiler R, Furrer MA. Giudici N, et al. Cancers (Basel). 2024 Feb 12;16(4):758. doi: 10.3390/cancers16040758. Cancers (Basel). 2024. PMID: 38398151 Free PMC article.
References
- Urology. 2005 Dec;66(6 Suppl 1):4-34 - PubMed
- J Urol. 2004 Dec;172(6 Pt 1):2177-81 - PubMed
- Eur Urol. 2010 Jun;57(6):963-9 - PubMed
- Eur Urol. 2002 Jan;41(1):30-3 - PubMed
- Urology. 1998 Oct;52(4):594-601 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical